Degenerative Meniscus Tears: Exercise Matches Surgery at 10 Years

For middle-aged adults with a degenerative meniscal tear, arthroscopic partial meniscectomy has not shown an objective physical-activity advantage over structured exercise—even 10 years later. In a Swedish randomized trial, patients assigned to surgery plus exercise and those assigned to exercise therapy alone recorded no statistically significant differences in steps, standing time, or sit-to-stand transitions on a week of wearable-sensor monitoring.

That result does not prove that every person with knee pain will recover without surgery. It does make a strong practical point: for the degenerative tears studied here, surgery did not deliver the long-term activity benefit many patients expect. Exercise remains the first treatment worth doing well.

A decade later, surgery added no measurable activity advantage

Sonesson et al.'s 2025 follow-up tracked 62 adults who had entered a randomized trial at ages 45 to 64 with degenerative meniscal symptoms. One group received exercise therapy; the other received knee arthroscopy followed by exercise therapy. At 10 years, participants wore an activPAL device for seven days. Unlike a questionnaire, the device records movement behavior directly.

In the intention-to-treat analysis—the analysis that preserves the original randomized assignments—the researchers found no statistically significant between-group difference in any accelerometer-derived physical-activity measure after adjustment for symptomatic osteoarthritis. Daily steps, time spent standing, and sit-to-stand transitions all told the same story: surgery plus exercise did not outperform exercise alone.

The trial's longer horizon matters. Knee procedures often sell themselves on a simple promise: remove the damaged tissue, then get people moving again. This study found no measurable extra movement a decade after that intervention. The result also fits earlier evidence reviewed by the authors. The sham-controlled FIDELITY trial, which enrolled 146 participants, found no difference between arthroscopy and placebo surgery in knee pain or function at 12 months; its five-year follow-up maintained that equivalence. In a separate two-year trial of 140 participants, Kise and colleagues found no difference in knee-function scores, while muscle strength favored exercise therapy.

Systematic reviews of randomized trials have likewise concluded that arthroscopic partial meniscectomy does not provide clinically meaningful benefit over sham surgery or structured exercise for degenerative tears. This evidence applies to degenerative meniscal disease, not acute traumatic tears in younger athletes.

The questionnaire result is interesting, but it does not overturn the sensor data

The same 10-year follow-up produced a striking split between what participants reported and what the activity monitor recorded. On the Saltin-Grimby physical-activity scale, 66% of the exercise-assigned group reported high-moderate activity, compared with 34% of the surgery-assigned group; the difference was statistically significant (p=0.015). Yet the activPAL data found no significant objective activity difference.

This does not establish that arthroscopy makes people less active. The sensor result does not support that conclusion. It does show that subjective and device-measured activity can diverge substantially after knee treatment. Recall, social expectations, fear of movement, and beliefs about an operated knee may shape questionnaires. The study cannot identify which explanation caused the gap.

Wearables are not magic truth machines; they measure selected behaviors over selected days. Still, they avoid the recall and reporting problems built into self-report scales. A 2022 systematic review by Singh et al. evaluated wearable activity trackers and pedometers in cancer survivors, where the devices functioned both as measurement tools and behavior-change interventions. That population differs from people with meniscal symptoms, so it cannot validate every orthopedic outcome. It does support the broader reason to value device-based activity measurement alongside patient-reported outcomes.

Exercise is treatment, not a waiting room before treatment

Exercise therapy does more than match surgery on the knee outcomes studied in these trials. It can improve capacity and health outside the knee, although those wider benefits do not prove that exercise repairs a meniscal tear or prevents osteoarthritis.

A 2026 meta-analytic compendium by Sheldon et al. pooled 146 controlled exercise-training studies in older adults. The analysis reported improvement in metabolic and inflammatory outcomes overall, with the exception of interleukin-1β. These are systemic biomarker and fitness findings, not evidence that a particular exercise program changes meniscal structure or eliminates knee symptoms. They still matter: a rehabilitation plan can improve more than the joint that brought someone to the clinic.

Cardiovascular evidence points in the same direction. A 2024 systematic review and meta-analysis by Ho et al. included 18 studies and 775 older adults and found that aerobic exercise improved arterial stiffness, including pulse-wave velocity (SMD −0.89; the abstract excerpt does not provide the confidence interval). This was not a study of meniscal tears, and arterial stiffness is not a knee outcome. It is a real health benefit that arthroscopic tissue removal cannot provide.

A 2022 review by Ma et al. also found that physical-activity interventions changed inflammatory cytokines and neuroprotective factors in 13 randomized trials involving 514 people with mild cognitive impairment. Those participants did not have degenerative knee disease, so the findings cannot demonstrate that exercise slows cartilage loss through cytokine changes. They provide biologic context, not proof of a meniscal mechanism.

What a serious non-surgical trial looks like

"Try physical therapy" can mean anything from a well-designed progressive program to three casual appointments and a photocopied handout. The trials compare surgery with structured exercise, not with doing nothing. A reasonable first-line plan should include supervised, progressive resistance work for the quadriceps and hip musculature, adjusted to pain and function, with documented attendance and progression over at least 12 weeks.

Patients who cannot tolerate heavy resistance may ask about blood-flow-restriction training. The evidence is narrower than the marketing. A 2021 systematic review and meta-analysis by Grantham et al. identified five randomized trials in knee osteoarthritis. It found low- to moderate-certainty evidence of no difference between blood-flow-restriction training and conventional resistance training in pain, self-reported function, objective function, strength, or muscle size. In other words, it may be a lower-load alternative when conventional training is difficult, but the available evidence does not show that it beats regular resistance training.

Why the trial is persuasive—and what it cannot answer

The Sonesson follow-up has clear strengths: random assignment, a 10-year time frame, and an objective activity endpoint. But it was small. The intention-to-treat sample included 62 people, roughly 30 to 32 per group, which limits precision and leaves the study underpowered for subgroup questions. A non-significant result means the trial found no demonstrated benefit; it is not a formal declaration that the treatments are statistically equivalent in every possible outcome.

Crossover also complicates interpretation. Eleven participants originally assigned to exercise later underwent arthroscopy, leaving 21 people in the non-surgery as-treated group and 41 in the surgery group. Intention-to-treat analysis remains the most reliable estimate of the effect of the original treatment strategy, but the groups were no longer pure exercise-only and surgery-only groups at 10 years.

The study came from one Swedish orthopedic center, where access to physiotherapy may not resemble every health system. Osteoarthritis was assessed with Kellgren-Lawrence grading on plain radiographs rather than MRI, which may miss earlier cartilage changes. The paper also did not report MRI-confirmed cartilage progression or total knee-replacement rates at 10 years. Those omissions matter because they are downstream outcomes patients care about.

Some clinicians still argue that patients with true mechanical locking, little radiographic osteoarthritis, or particular symptom patterns may benefit from surgery. The existing randomized evidence has not established a sensor-confirmed long-term benefit for such a subgroup. A large, adequately powered trial with prespecified subgroups and objective outcomes could change that answer.

For a degenerative meniscal tear, start by giving structured exercise an honest trial. Ask what the surgery is expected to improve, compared with a progressive rehabilitation program, and whether that expectation has been shown in randomized evidence for someone like you.

Arthroscopic partial meniscectomy may still enter the conversation after persistent symptoms despite well-delivered rehabilitation, or when the diagnosis falls outside this evidence base. But the current long-term trial does not support treating it as the faster route to a more active life. For the patients studied, exercise reached the same objective destination without adding an operation.